Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 (0) 1494 818026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+44 (0) 1494 818026

Testimonials
I would highly recommend the service of Zenopa. It remained very professional throughout and aided me in getting my current position with Covidien.
Gareth, 2011

GlaxoSmithKline agrees latest OTC brand sale

21 March 2012 00:00 in Consumer Healthcare News


GlaxoSmithKline has provided an update on its strategy of selling off a number of non-core over-the-counter (OTC) brands, highlighting several recent deals it has been able to conclude.

The healthcare company has agreed a 391 million pound arrangement with Omega Pharma that will see the latter firm take control of brands such as Lactacyd, Abtei, Solpadeine, Zantac, Nytol and Beconase.

This transaction also encompasses the Herrenberg manufacturing site in Germany, which employs approximately 110 people, and follows the successful sale of a number of product lines to Prestige Brands Holdings in the US and Canada last December.

GlaxoSmithKline is selling off these brands in order to simplify its consumer portfolio, with discussions still ongoing over a number of additional product lines.

Simon Dingemans, GlaxoSmithKline's chief financial officer, said: "Given the continued economic challenges across the eurozone, I am pleased that we have been able to transact these assets at a good price for GlaxoSmithKline."

Earlier this month, Chemist and Druggist reported plans by the company to launch an innovative trial of a new chronic obstructive pulmonary disease via UK pharmacies.ADNFCR-8000103-ID-801323482-ADNFCR

Other news stories from 21/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd